Rely on the most comprehensive, up-to-date legal content designed and curated by lawyers for lawyers
Work faster and smarter to improve your drafting productivity without increasing risk
Accelerate the creation and use of high quality and trusted legal documents and forms
Streamline how you manage your legal business with proven tools and processes
Manage risk and compliance in your organisation to reduce your risk profile
Stay up to date and informed with insights from our trusted experts, news and information sources
Access the best content in the industry, effortlessly — confident that your news is trustworthy and up to date.
Find up-to-date guidance on points of law and then easily pull up sources to support your advice with Lexis PSL
Check out our straightforward definitions of common legal terms.
Speed up all aspects of your legal work with tools that help you to work faster and smarter.
Our trusted tax intelligence solutions, highly-regarded exam training and education materials help guide and tutor Tax professionals
Access our unrivalled global news content, business information and analytics solutions
Insurance, risk and compliance intelligence using big data, proprietary linking and advanced analytics.
A leading provider of software platforms for professional services firms
In-depth analysis, commentary and practical information to help you protect your business
LexisNexis Blogs shed light on topics affecting the legal profession and the issues you're facing
Our latest thinking on key legal industry developments
Legal professionals trust us to help navigate change. Find out how we help ensure they exceed expectations
Discuss the latest legal developments, ask questions, and share best practice with other LexisPSL subscribers
On 20 April 2020, Midatech Pharma plc (Midatech) announced that it is undergoing a formal sale process (FSP) as part of its ongoing strategic review announced on 31 March 2020. The board is hoping to conclude the FSP by the third quarter of 2020.
Midatech have stated ‘prevailing conditions in the capital markets’ as the reason for implementing the strategic review. These conditions ultimately led to the biotech company being unable to raise sufficient funds for the timely completion of its Phase III clinical programme of MTD201 (for the treatment of the hormonal disorder, acromegaly) and the manufacturing scale-up of its Bilbao facility, despite $8.5 million in loans from the Spanish government. Closing the Bilbao facility and shutting any further inhouse developments of its MTD201 programme resulted in a total of 47 people being made redundant, including 5 UK-based employees.
The company also announced that, unless it is able to secure a grant under the EU EIC Accelerator SME, it may also have to cancel its GlioKIDS Phase II trial of MTX110, for the treatment of childhood brain cancer.
As part of the strategic review the board has stated that it is ‘considering all options for extracting value from its technologies. These include partnering its clinical stage assets; MTD201, MTX110 and MTX114 (for psoriasis) and/or partnering existing and upcoming proof of concept formulations’.
Market Tracker will continue to monitor this transaction as it develops.
Free trials are only available to individuals based in the UK
* denotes a required field
0330 161 1234